
## Peter Vadas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10946361/publications.pdf Version: 2024-02-01



DETED VADAS

#	Article	IF	CITATIONS
1	Reproducibility of Symptom Sequences Across Episodes of Recurrent Anaphylaxis. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 534-538.e1.	2.0	7
2	Plateletâ€activating factor acetylhydrolase is a biomarker of severe anaphylaxis in children. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2665-2676.	2.7	12
3	The platelet-activating factor pathway in food allergy and anaphylaxis. Annals of Allergy, Asthma and Immunology, 2016, 117, 455-457.	0.5	12
4	Platelets in the immune response: Revisiting platelet-activating factor in anaphylaxis. Journal of Allergy and Clinical Immunology, 2015, 135, 1424-1432.	1.5	99
5	Potential Therapeutic Strategies for Severe Anaphylaxis Targeting Platelet-Activating Factor and PAF Acetylhydrolase. Current Treatment Options in Allergy, 2014, 1, 232-246.	0.9	6
6	Relationship between platelet activating factor acetylhydrolase activity and apolipoprotein B levels in patients with peanut allergy. Allergy, Asthma and Clinical Immunology, 2014, 10, 20.	0.9	18
7	Reply. Journal of Allergy and Clinical Immunology, 2013, 131, 1714-1715.	1.5	0
8	Anaphylaxis: Clinical features and mediator release patterns. Journal of Allergy and Clinical Immunology, 2013, 132, 1456-1457.	1.5	3
9	Heterogeneity in presentation and treatment of catamenial anaphylaxis. Annals of Allergy, Asthma and Immunology, 2013, 111, 107-111.	0.5	29
10	Platelet-activating factor, histamine, and tryptase levels in human anaphylaxis. Journal of Allergy and Clinical Immunology, 2013, 131, 144-149.	1.5	185
11	Methylene blue for the treatment of refractory anaphylaxis without hypotension. American Journal of Emergency Medicine, 2013, 31, 264.e3-264.e5.	0.7	29
12	Effect of epinephrine on platelet-activating factor–stimulated human vascular smooth muscle cells. Journal of Allergy and Clinical Immunology, 2012, 129, 1329-1333.	1.5	41
13	Concurrent blockade of platelet-activating factor and histamine prevents life-threatening peanut-induced anaphylactic reactions. Journal of Allergy and Clinical Immunology, 2009, 124, 307-314.e2.	1.5	92
14	Peanut Allergy: An Overview. Allergy, Asthma and Clinical Immunology, 2008, 4, 139.	0.9	28
15	Platelet-Activating Factor, PAF Acetylhydrolase, and Severe Anaphylaxis. New England Journal of Medicine, 2008, 358, 28-35.	13.9	476
16	Detection of Peanut Allergens in Breast Milk of Lactating Women. JAMA - Journal of the American Medical Association, 2001, 285, 1746.	3.8	180
17	Regulation of the cellular expression of secretory and cytosolic phospholipases A2, and cyclooxygenase-2 by peptide growth factors. Biochimica Et Biophysica Acta - Molecular Cell Research, 1998, 1403, 47-56.	1.9	55
18	Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine. Biochemical Pharmacology, 1997, 53, 1901-1907.	2.0	45

Peter Vadas

#	Article	IF	CITATIONS
19	Group II phospholipases A2 are indirectly cytolytic in the presence of exogenous phospholipid. Lipids and Lipid Metabolism, 1997, 1346, 193-197.	2.6	12
20	Secretory Non-Pancreatic Phospholipase A2 and cyclooxygenase-2 Expression by Tracheobronchial Smooth Muscle Cells. FEBS Journal, 1996, 235, 557-563.	0.2	38
21	A Natural Disruption of the Secretory Group II Phospholipase A2 Gene in Inbred Mouse Strains. Journal of Biological Chemistry, 1995, 270, 22378-22385.	1.6	308
22	Inhibition of human group II phospholipase A2 by C-reactive protein in vitro. Journal of Lipid Mediators and Cell Signalling, 1995, 11, 187-200.	1.0	8
23	Phospholipase A2 and the Pathogenesis of Multisystem Organ Failure in Experimental and Clinical Endotoxin Shock. , 1994, , 203-211.		0
24	Association of hyperphospholipasemia A2 with multiple system organ dysfunction due to salicylate intoxication. Critical Care Medicine, 1993, 21, 1087-1091.	0.4	25
25	Inhibition of enzymatic activity of phospholipases A2 by minocycline and doxycycline. Biochemical Pharmacology, 1992, 44, 1165-1170.	2.0	123
26	Induction of circulating phospholipase A2by intravenous administration of recombinant human tumour necrosis factor. Mediators of Inflammation, 1992, 1, 235-240.	1.4	3
27	Cortisol response to corticotropin and survival in septic shock. Lancet, The, 1991, 337, 1230-1231.	6.3	1
28	Comparison of group I and II soluble phospholipases A2 activities on phagocytic functions of human polymorphonuclear and mononuclear phagocytes. Inflammation, 1991, 15, 127-135.	1.7	19
29	Phospholipase A2 Activation is the Pivotal Step in the Effector Pathway of Inflammation. Advances in Experimental Medicine and Biology, 1990, 275, 83-101.	0.8	20
30	Pathogenesis of hypotension in septic shock. Critical Care Medicine, 1988, 16, 1-7.	0.4	129
31	Purification of a Soluble Phospholipase A2 from Synovial Fluid in Rheumatoid Arthritis1. Journal of Biochemistry, 1986, 100, 1297-1303.	0.9	86
32	Inflammatory Effect of Intradermal Administration of Soluble Phospholipase A2 in Rabbits. Journal of Investigative Dermatology, 1986, 86, 380-383.	0.3	65
33	Characterization of extracellular phospholipase A2 in rheumatoid synovial fluid. Life Sciences, 1985, 36, 579-587.	2.0	111
34	Involvement of circulating phospholipase A2 in the pathogenesis of the hemodynamic changes in endotoxin shock. Canadian Journal of Physiology and Pharmacology, 1983, 61, 561-566.	0.7	93
35	The efficacy of anti-inflammatory agents with respect to extracellular phospholipase A2 activity. Life Sciences, 1982, 30, 155-162.	2.0	32
36	Extracellular phospholipase A2 mediates inflammatory hyperaemia. Nature, 1981, 293, 583-585.	13.7	87

#	Article	IF	CITATIONS
37	The release of phospholipase A2 from aggregated platelets and stimulated macrophages of sheep. Life Sciences, 1980, 26, 1721-1729.	2.0	51